Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) reported disappointing results from a Phase 2 LIBERTY study in pulmonary arterial hypertension sending the stock price crashing $7.90 to close at $8.10.
Eiger BioPharmaceuticals reports disappointing study results
January 16, 2018 at 16:34 PM EST